Denali Therapeutics Inc. 8-K

What Happened Denali Therapeutics Inc. filed an 8-K reporting the closing of a synthetic royalty funding agreement (the “Royalty Agreement”) with Royalty Pharma. The company entered the Royalty Agreement on December 4, 2025, and on March 27, 2026 received $200.0 million in gross proceeds in connection with the closing. The closing followed the U.S. Food and Drug Administration’s accelerated approval of tividenofusp alfa on March 24, 2026. The report was signed by Alexander O. Schuth, M.D., Chief Operating and Financial Officer, on March 31, 2026.

Key Details

• Royalty Agreement entered: December 4, 2025 (material definitive agreement with Royalty Pharma).
• Closing and funding date: March 27, 2026; gross proceeds received: $200.0 million.
• FDA action: accelerated approval of tividenofusp alfa on March 24, 2026, preceded the funding.
• Filing items: Item 1.01 (material agreement), Item 2.03 (creation of a direct financial obligation), Item 7.01 (Regulation FD disclosure).

Why It Matters The transaction provides Denali with a $200M cash infusion tied to the approved product tividenofusp alfa and establishes a contractual royalty-related financial obligation to Royalty Pharma. For investors, this affects the company’s near-term liquidity position and creates future payment obligations under the Royalty Agreement; monitor upcoming disclosures for details on how proceeds will be used and the specific royalty or payment terms.